WallStreetZenWallStreetZen

NASDAQ: CTXR
Citius Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for CTXR

Based on 3 analysts offering 12 month price targets for Citius Pharmaceuticals Inc.
Min Forecast
$4.00+309.84%
Avg Forecast
$6.67+582.99%
Max Forecast
$10.00+924.59%

Should I buy or sell CTXR stock?

Based on 3 analysts offering ratings for Citius Pharmaceuticals Inc.
Strong Buy
Strong Buy
3 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their CTXR stock forecasts and price targets.

Forecast return on equity

Is CTXR forecast to generate an efficient return?
Company
N/A
Industry
-0.1%
Market
28.88%

Forecast return on assets

Is CTXR forecast to generate an efficient return on assets?
Company
N/A
Industry
0.01%

CTXR earnings per share forecast

What is CTXR's earnings per share in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$0.19
Avg 2 year Forecast
$0.96
Avg 3 year Forecast
$1.36

CTXR revenue forecast

What is CTXR's revenue in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$103.8M
Avg 2 year Forecast
$290.4M
Avg 3 year Forecast
$436.2M

CTXR vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CTXR$0.98$6.67+582.99%Strong Buy
RPHM$5.86$21.33+264.04%Strong Buy
ELVN$21.95$1.00-95.44%Hold
GRPH$2.43$5.57+129.26%Hold
CRMD$3.42$14.75+331.29%Buy
View Top Biotech Stocks

Citius Pharmaceuticals Stock Forecast FAQ

Is Citius Pharmaceuticals Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: CTXR) stock is to Strong Buy CTXR stock.

Out of 3 analysts, 3 (100%) are recommending CTXR as a Strong Buy, 0 (0%) are recommending CTXR as a Buy, 0 (0%) are recommending CTXR as a Hold, 0 (0%) are recommending CTXR as a Sell, and 0 (0%) are recommending CTXR as a Strong Sell.

If you're new to stock investing, here's how to buy Citius Pharmaceuticals stock.

What is CTXR's earnings growth forecast for 2023-2025?

(NASDAQ: CTXR) Citius Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.24%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.48%.

Citius Pharmaceuticals's earnings in 2023 is -$28,009,071.On average, 2 Wall Street analysts forecast CTXR's earnings for 2023 to be $27,788,981, with the lowest CTXR earnings forecast at -$5,850,312, and the highest CTXR earnings forecast at $59,965,697. On average, 1 Wall Street analyst forecast CTXR's earnings for 2024 to be $140,407,485, with the lowest CTXR earnings forecast at $140,407,485, and the highest CTXR earnings forecast at $140,407,485.

In 2025, CTXR is forecast to generate $198,910,604 in earnings, with the lowest earnings forecast at $198,910,604 and the highest earnings forecast at $198,910,604.

What is CTXR's revenue growth forecast for 2023-2025?

(NASDAQ: CTXR) Citius Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 40.95%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.76%.

Citius Pharmaceuticals's revenue in 2023 is $0.On average, 2 Wall Street analysts forecast CTXR's revenue for 2023 to be $15,174,977,728, with the lowest CTXR revenue forecast at $10,676,819,181, and the highest CTXR revenue forecast at $19,673,136,274. On average, 1 Wall Street analysts forecast CTXR's revenue for 2024 to be $42,474,726,827, with the lowest CTXR revenue forecast at $42,474,726,827, and the highest CTXR revenue forecast at $42,474,726,827.

In 2025, CTXR is forecast to generate $63,799,113,629 in revenue, with the lowest revenue forecast at $63,799,113,629 and the highest revenue forecast at $63,799,113,629.

What is CTXR's forecast return on assets (ROA) for 2023-2026?

(NASDAQ: CTXR) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 0.01%.

What is CTXR's Price Target?

According to 3 Wall Street analysts that have issued a 1 year CTXR price target, the average CTXR price target is $6.67, with the highest CTXR stock price forecast at $10.00 and the lowest CTXR stock price forecast at $4.00.

On average, Wall Street analysts predict that Citius Pharmaceuticals's share price could reach $6.67 by Aug 15, 2023. The average Citius Pharmaceuticals stock price prediction forecasts a potential upside of 582.99% from the current CTXR share price of $0.98.

What is CTXR's Earnings Per Share (EPS) forecast for 2023-2025?

(NASDAQ: CTXR) Citius Pharmaceuticals's current Earnings Per Share (EPS) is -$0.18. On average, analysts forecast that CTXR's EPS will be $0.19 for 2023, with the lowest EPS forecast at -$0.04, and the highest EPS forecast at $0.41. On average, analysts forecast that CTXR's EPS will be $0.96 for 2024, with the lowest EPS forecast at $0.96, and the highest EPS forecast at $0.96. In 2025, CTXR's EPS is forecast to hit $1.36 (min: $1.36, max: $1.36).

What is CTXR's forecast return on equity (ROE) for 2023-2026?

(NASDAQ: CTXR) forecast ROE is N/A, which is considered weak.
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTube
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.